How a simple dietary change may slow liver cancer in at-risk patients
People with compromised liver function may be able to reduce their risk of liver cancer or slow its progression with a simple dietary change: eating less protein. A… read more.
People with compromised liver function may be able to reduce their risk of liver cancer or slow its progression with a simple dietary change: eating less protein. A… read more.
The study shows that this drug pair works far better together than either agent alone, offering a realistic and potentially fast path toward a new antifibrotic therapy. Liver… read more.
Novo Nordisk presented data at the 76th annual American Association for the Study of Liver Diseases (AASLD) meeting, The Liver Meeting 2025, in Washington, D.C., evaluating the effects… read more.
Eisai and Merck & Co., Inc., (known as MSD outside of the United States and Canada) announced results from that Phase III LEAP-012 trial evaluating Lenvima (lenvatinib), the… read more.
MetaVia Inc a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, announced that an abstract highlighting data on Vanoglipel (DA-1241), a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, has… read more.
Metabolic dysfunction-associated steatotic liver disease is the most common liver disease in the world, affecting about one third of the adult population. This disorder is characterized by the… read more.
NICE(UK): Durvalumab with tremelimumab can be used, within its marketing authorisation, as an option for untreated advanced or unresectable hepatocellular carcinoma (HCC) in adults. Durvalumab with tremelimumab can… read more.
Madrigal Pharmaceuticals Inc. announced that the European Commission (EC) has granted conditional marketing authorization for Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic MASH with moderate to… read more.
Novo Nordisk announced that the FDA has approved an additional indication for Wegovy (semaglutide 2.4 mg) based on a supplemental New Drug Application (sNDA) for treatment of noncirrhotic… read more.
UC Davis Health researchers have discovered that a natural molecule made by gut bacteria can reverse liver damage and repair the gut lining after aflatoxin exposure. The treatment may offer… read more.
The introduction of artificial intelligence (AI) to assist colonoscopies is linked to a reduction in the ability of endoscopists (health professionals who perform colonoscopies) to detect precancerous growths… read more.
Americans who drink heavily are more than twice as likely to develop significant liver disease compared to 20 years ago, according to a new Keck Medicine of USC study published today… read more.
Advertisment